Story perspectives

Trump Gets Regeneron Price Cuts, $10 B Pledge, Gene Therapy Approval

4/24/2026

30 3

Summary

Trump Announces Deal

President Donald Trump announced a drug-price deal with Regeneron on April 23, 2026.
Regeneron will cut Medicaid prices, sell Praluent for $225 on TrumpRx.gov, and pledge $10 billion in the United States.
The FDA approved Regeneron’s gene therapy Otarmeni for hearing loss and will provide it to patients.
Health and Human Services (HHS) counselor Chris Klomp reported agreements cover 86 percent of drug market and that Democrats urged Health Secretary Robert F. Kennedy Jr. to release terms.

Summary

FDA Approves Otarmeni

The FDA approved Otarmeni, a gene therapy for OTOF-related hearing loss affecting about 20-50 newborns annually, under the new National Priority Voucher program, the first gene therapy to receive such a voucher.
President Donald Trump said the Regeneron agreement will help him win the midterms.
Critics noted most price cuts apply to Medicaid, doubting they will lower out-of-pocket costs, and said Deaf community members questioned the therapy’s broader impact.

1 of 2

Trump Announces Deal

President Donald Trump announced a drug-price deal with Regeneron on April 23, 2026.
Regeneron will cut Medicaid prices, sell Praluent for $225 on TrumpRx.gov, and pledge $10 billion in the United States.
The FDA approved Regeneron’s gene therapy Otarmeni for hearing loss and will provide it to patients.
Health and Human Services (HHS) counselor Chris Klomp reported agreements cover 86 percent of drug market and that Democrats urged Health Secretary Robert F. Kennedy Jr. to release terms.

1 / 2